Abstract
The effect of Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)-6H-[1]benzothieno[2,3-b][1,5]benzodiazepin e maleate), a novel potential atypical antipsychotic candidate, in producing dystonia in Cebus monkeys was investigated. Y-931 induced relatively weak dystonia in several observation periods at doses greater than 0.1 mg/kg, i.m. Although Y-931 significantly increased total dystonia scores (the sum of 15 to 360 min after injection) at doses greater than 0.5 mg/kg, i.m., the scores did not exceed 20, up to a dose of 1.0 mg/kg, i.m. and lacked a dose-response relationship. The present result suggests that Y-931 is predicted to have a low risk of extrapyramidal side effects.
Original language | English (US) |
---|---|
Pages (from-to) | 364-366 |
Number of pages | 3 |
Journal | Journal of Pharmacological Sciences |
Volume | 93 |
Issue number | 3 |
DOIs | |
State | Published - Nov 2003 |
Externally published | Yes |
Fingerprint
Keywords
- Dystonia
- Monkey
- Y-931
ASJC Scopus subject areas
- Pharmacology
Cite this
Effect of a novel potential atypical antipsychotic drug, Y-931, in producing dystonia in Cebus monkeys. / Shiigi, Yasuyuki; Maeda, Jun Ichi; Yasumatsu, Hiroshi; Tanaka, Hiroshi; Casey, Daniel.
In: Journal of Pharmacological Sciences, Vol. 93, No. 3, 11.2003, p. 364-366.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of a novel potential atypical antipsychotic drug, Y-931, in producing dystonia in Cebus monkeys
AU - Shiigi, Yasuyuki
AU - Maeda, Jun Ichi
AU - Yasumatsu, Hiroshi
AU - Tanaka, Hiroshi
AU - Casey, Daniel
PY - 2003/11
Y1 - 2003/11
N2 - The effect of Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)-6H-[1]benzothieno[2,3-b][1,5]benzodiazepin e maleate), a novel potential atypical antipsychotic candidate, in producing dystonia in Cebus monkeys was investigated. Y-931 induced relatively weak dystonia in several observation periods at doses greater than 0.1 mg/kg, i.m. Although Y-931 significantly increased total dystonia scores (the sum of 15 to 360 min after injection) at doses greater than 0.5 mg/kg, i.m., the scores did not exceed 20, up to a dose of 1.0 mg/kg, i.m. and lacked a dose-response relationship. The present result suggests that Y-931 is predicted to have a low risk of extrapyramidal side effects.
AB - The effect of Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)-6H-[1]benzothieno[2,3-b][1,5]benzodiazepin e maleate), a novel potential atypical antipsychotic candidate, in producing dystonia in Cebus monkeys was investigated. Y-931 induced relatively weak dystonia in several observation periods at doses greater than 0.1 mg/kg, i.m. Although Y-931 significantly increased total dystonia scores (the sum of 15 to 360 min after injection) at doses greater than 0.5 mg/kg, i.m., the scores did not exceed 20, up to a dose of 1.0 mg/kg, i.m. and lacked a dose-response relationship. The present result suggests that Y-931 is predicted to have a low risk of extrapyramidal side effects.
KW - Dystonia
KW - Monkey
KW - Y-931
UR - http://www.scopus.com/inward/record.url?scp=0346874516&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0346874516&partnerID=8YFLogxK
U2 - 10.1254/jphs.93.364
DO - 10.1254/jphs.93.364
M3 - Article
C2 - 14646255
AN - SCOPUS:0346874516
VL - 93
SP - 364
EP - 366
JO - Journal of Pharmacological Sciences
JF - Journal of Pharmacological Sciences
SN - 1347-8648
IS - 3
ER -